CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes

David Gonzalez,[1,2] Monica Else,[1] Dorte Wren,[2] Monica Usai,[2] Anne Mette Buhl,[3] Anton Parker,[4] David Oscier,[4] Gareth Morgan,[1] and Daniel Catovsky[1]

[1]Haemato-Oncology Research Unit, Division of Molecular Pathology, The Institute of Cancer Research, London, UK; [2]Molecular Diagnostics, The Royal Marsden NHS Foundation Trust, London, UK; [3]The Leukemia Laboratory, Department of Hematology, Rigshospitalet and University of Copenhagen, Denmark, and [4]Department of Haematology, Royal Bournemouth Hospital, UK

Online Supplementary Table S1. Availability of CLLU1 expression data by patient/disease characteristics.

| | Variable | Total | CLLU1 expression data available | | P |
			Yes n. (%)	No n. (%)	
Gender					
	Female	204	137 (27)	67 (26)	0.8
	Male	573	378 (73)	195 (74)	
Treatment allocation					
	Chlorambucil	387	246 (48)	141 (54)	0.1
	Fludarabine	194	128 (25)	66 (25)	
	Fludarabine +Cyclophosphamide	196	141 (27)	55 (21)	
Age group (years)	<60	255	160 (31)	95 (36)	0.2
	60-69	288	199 (39)	89 (34)	
	70+	234	156 (30)	78 (30)	
Binet stage					
	A progressive	191	132 (26)	59 (22)	0.5
	B	352	227 (44)	125 (48)	
	C	234	156 (30)	78 (30)	
β_2 microglobulin					
	<4 mg/L	309	190 (53)	119 (60)	0.1
	≥4 mg/L	247	168 (47)	79 (40)	
IGHV gene (98% cut off)					
	Unmutated	327	290 (62)	37 (57)	0.4
	Mutated	206	178 (38)	28 (43)	
TP53 deletion (10% cut off) and/or mutation					
	No	532	437 (92)	95 (92)	0.8
	Yes	48	40 (8)	8 (8)	
11q deletion (5% cut off)					
	No	463	376 (79)	87 (82)	0.5
	Yes	116	97 (21)	19 (18)	
Trisomy 12 (3% cut off)					
	No	488	404 (85)	84 (79)	0.1
	Yes	91	69 (15)	22 (21)	
CD38 (7% cut off)					
	No	201	157 (36)	44 (43)	0.2
	Yes	334	275 (64)	59 (57)	
ZAP-70 (10% cut off)					
	No	242	220 (51)	22 (47)	0.6
	Yes	236	211 (49)	25 (53)	
13q deletion (5% cut off)					
	No	233	193 (41)	40 (38)	0.6
	Yes	346	280 (59)	66 (62)	